We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · August 10, 2022

Effect of High-Dose Anti-VEGF Therapy for Treatment-Resistant Neovascular AMD

Graefe's Archive for Clinical and Experimental Ophthalmology


Additional Info

Graefe's Archive for Clinical and Experimental Ophthalmology
Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration
Graefes Arch. Clin. Exp. Ophthalmol 2022 Jul 01;260(7)2239-2247, GK Broadhead, TDL Keenan, EY Chew, HE Wiley, CA Cukras

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading